Hsbc Holdings PLC Sells 98,228 Shares of Sanofi $SNY

Hsbc Holdings PLC cut its holdings in shares of Sanofi (NASDAQ:SNY) by 47.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 107,689 shares of the company’s stock after selling 98,228 shares during the period. Hsbc Holdings PLC’s holdings in Sanofi were worth $5,220,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. Flagship Harbor Advisors LLC acquired a new position in Sanofi in the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. grew its holdings in Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after acquiring an additional 379 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi during the 3rd quarter valued at $29,000. Leonteq Securities AG lifted its stake in shares of Sanofi by 95.8% in the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after purchasing an additional 297 shares during the period. Finally, Palisade Asset Management LLC acquired a new position in shares of Sanofi in the 3rd quarter valued at $30,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the subject of a number of analyst reports. Wall Street Zen cut Sanofi from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Argus raised Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Morgan Stanley set a $49.00 target price on Sanofi in a report on Wednesday, July 8th. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Finally, BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, Sanofi currently has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Down 1.0%

Sanofi stock opened at $43.36 on Friday. The company has a 50 day moving average of $43.43 and a 200-day moving average of $45.37. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68. The stock has a market capitalization of $105.12 billion, a PE ratio of 12.11, a price-to-earnings-growth ratio of 1.11 and a beta of 0.34.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.